Quellenangaben 


   1. S. Rizvi, S. A. Khan, C. L. Hallemeier et al. Cholangiocarcinoma -- 
      evolving concepts and therapeutic strategies. Nature reviews Clinical 
      oncology. 2018 (15), 95-111 
 
   2. FIDES-01: ClinicalTrials.gov-Identifier: NCT03230318. 
 
   3. T. G. Hall, Y. Yu, S. Eathiraj et al. Preclinical activity of ARQ 087, a 
      novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016, 11 (9), 
      e0162594 
 
   4. R. Porta, R. Borea, A. Coelho et al. FGFR a promising druggable target in 
      cancer: Molecular biology and new drugs. Critical Reviews in 
      Oncology/Hematology 2017 (113), 256-267 
 
   5. T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer: 
      Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer 
      Research 2016 (22), 259-267 
 
   6. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A 
      dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer. 
      Molecular Cancer Therapeutics 2019 (18), 12 Supplement, pp. LB-C12 
 
   7. M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1 
      receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy 
      of Cancer 2017, 5:53 
 
   8. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms 
      tumor-infiltrating macrophages and improves response to T cell checkpoint 
      immunotherapy in pancreatic cancer models. Cancer Research 2014 (74), 
      5057-5069 
 
   9. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells 
      from reaching tumor cells and limit the efficacy of anti--PD-1 treatment. 
      Proceedings of the National Academy of Science of the United States of 
      America 2018 (115), E4041-E4050 
 
  10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib 
      (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive 
      intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120), 
      165-171. ClinicalTrials.gov-Identifier: NCT01752920 
 
  11. FIDES-02: ClinicalTrials.gov-Identifier: NCT04045613 
 
  12. FIDES-03: ClinicalTrials.gov-Identifier: NCT04604132 
 
  13. S. K. Saha, A. X. Zhu, C. S. Fuchs et al. Forty-year trends in 
      cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the 
      rise. The Oncologist 2016 (21), 594-599 
 
  14. A. Lamarca, D. H. Palmer, H. S. Wasa et al. Second-line FOLFOX 
      chemotherapy versus active symptom control for advanced biliary tract 
      cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. 
      Lancet Oncology 2021 (22):690-701

Anhang 


   -- Pressemitteilung (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/1c32807a-261d-4372-ad1e-ad11632b92a8

(END) Dow Jones Newswires

September 17, 2021 01:15 ET (05:15 GMT)